Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells $373,898.88 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 8,406 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $44.48, for a total value of $373,898.88. Following the sale, the insider owned 100,558 shares of the company’s stock, valued at $4,472,819.84. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Mo Qatanani also recently made the following trade(s):

• On Thursday, January 22nd, Mo Qatanani sold 14,898 shares of Scholar Rock stock. The stock was sold at an average price of $46.71, for a total transaction of $695,885.58.
• On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The stock was sold at an average price of $45.20, for a total transaction of $592,662.40.
• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02.

Scholar Rock Trading Down 7.3%

NASDAQ SRRK opened at $44.29 on Friday. Scholar Rock Holding Corporation has a 52-week low of $22.71 and a 52-week high of $48.28. The firm has a 50-day moving average price of $43.73 and a 200 day moving average price of $37.30. The stock has a market capitalization of $4.52 billion, a P/E ratio of -14.06 and a beta of 0.63. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period last year, the firm earned ($0.66) earnings per share. Equities research analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a research note on Friday, November 14th. Barclays increased their target price on shares of Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday. Bank of America assumed coverage on Scholar Rock in a report on Thursday, October 9th. They issued a “buy” rating and a $53.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $50.14.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Three Seasons Wealth LLC grew its holdings in Scholar Rock by 2.1% during the 4th quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock valued at $483,000 after buying an additional 222 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Scholar Rock by 7.9% in the third quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock worth $231,000 after acquiring an additional 456 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Scholar Rock by 15.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,668 shares of the company’s stock valued at $130,000 after acquiring an additional 500 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of Scholar Rock by 0.9% in the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock valued at $2,209,000 after acquiring an additional 577 shares in the last quarter. Finally, Tema Etfs LLC boosted its stake in shares of Scholar Rock by 6.6% during the fourth quarter. Tema Etfs LLC now owns 9,899 shares of the company’s stock valued at $436,000 after acquiring an additional 616 shares during the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).